Auris Medical initiated its first clinical trial with AM-101, its investigational drug for the treatment of inner ear tinnitus. The primary objective of the double blind, randomised, placebo-controlled trial with dose escalation is to evaluate the safety of intratympanically delivered AM-101 in patients suffering from tinnitus following acute noise trauma.
